AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE - Generic Drug Details

What are the generic sources for amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride and what is the scope of freedom to operate?

Amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride is the generic ingredient in ten branded drugs marketed by Baxter Hlthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

US Patents:	0
Tradenames:	10
Applicants:	1
NDAs:	1
Clinical Trials:	56
DailyMed Link:	AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nextrast, Inc.	PHASE1
Mario Negri Institute for Pharmacological Research	PHASE3
BeiGene	PHASE2

See all AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

A12CA	Sodium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CC	Magnesium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05BA	Solutions for parenteral nutrition
B05B	I.V. SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05CB	Salt solutions
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-009	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-002	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-010	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-006	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-005	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-007	Oct 23, 1995		DISCN	No	No
Baxter Hlthcare	TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-001	Oct 23, 1995		DISCN	No	No

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Overview and Financial Trajectory for Intravenous Electrolyte Solutions

The global market for intravenous electrolyte solutions comprising amino acids, dextrose, magnesium chloride, potassium phosphate dibasic, sodium acetate, and sodium chloride exhibits steady growth driven by expanding healthcare needs, aging populations, and increased incidence of electrolyte imbalances. The market is characterized by high competition, significant R&D activity, and a diverse array of manufacturers ranging from large pharmaceutical companies to generic producers.

Market Size and Growth Estimates

The global intravenous fluids market was valued at approximately USD 14 billion in 2022 and is projected to grow at a CAGR of 4-6% through 2028, reaching nearly USD 20 billion. Electrolyte solutions constitute a substantial segment, accounting for roughly 35-40% of the total, driven by their widespread use in hospitals, clinics, and emergency settings.

Key Market Drivers

• Aging Population: Increasing prevalence of chronic conditions like kidney disorders and dehydration elevates demand.
• Hospitalization Rates: Rising admissions for surgeries, trauma, and critical care elevate intravenous therapy needs.
• Electrolyte Imbalance Management: Growing awareness of electrolyte regulation benefits prompts higher utilization.

Major Market Segments and Utilization

Component	Percentage of Electrolyte Solutions Market	Notes
Sodium chloride	50%	Standard maintenance fluid, most widely used
Dextrose solutions	25%	Energy provision, combined with electrolytes
Potassium-based solutions	8%	Severe electrolyte imbalance correction
Magnesium solutions	7%	Used in magnesium deficiency or pre-eclampsia
Phosphate solutions	5%	Rare but necessary in specific deficiencies
Amino acids solutions	5%	Parenteral nutrition formulations
Sodium acetate solutions	2%	Less common, useful in acidosis management

Financial Trajectory and Revenue Dynamics

• Major Players: Baxter International, B. Braun Melsungen AG, Fresenius Kabi, and Huiying Medical, collectively command over 70% of the market.
• Pricing Trends: Inpatient dialysis-grade solutions average USD 0.50 to USD 1.50 per liter, depending on formulation complexity and brand.
• Research and Development: Investments focus on stability, biocompatibility, and novel delivery formats including pre-mixed, ready-to-use solutions.

Regulatory and Economic Factors

• Regulatory Environment: Stringent approval processes governed by FDA, EMA, and other agencies impact market entry and manufacturing costs.
• Pricing Pressures: Insurance reimbursement policies and hospital procurement negotiations limit profit margins.
• Patent Landscape: Patents on proprietary formulations and delivery systems expire, increasing generic competition.

Financial Outlook

Year	Estimated Market Size (USD billion)	Key Growth Factors
2023	14.5	Recovery from COVID-19 disruptions
2024	15.3	Increasing chronic disease prevalence
2025	16.2	Expansion of outpatient infusion therapy
2026	17.4	Technological advances and automation
2028	19.8	Market maturity and regional expansion

The trajectory suggests moderate but sustained growth facilitated by clinical adoption and technological innovation.

Proprietary, Market Entry, and Investment Considerations

• Emerging Formulations: Biocompatible, pH-stable, pre-mixed formulations gain favor; innovation lowers competition barriers.
• Regional Growth: Asia-Pacific and Latin America show faster CAGR (6-8%) due to increased healthcare infrastructure investments.
• Intellectual Property Risks: Patent expirations and off-patent formulations encourage generic entry, reducing unit costs.

Key Takeaways

• The intravenous electrolyte solutions market will expand with a CAGR of 4-6% from 2023-2028.
• Sodium chloride solutions dominate with 50% market share; amino acids and phosphate solutions are smaller but high-value segments.
• Major firms control 70% of the market, with price pressures and regulation affecting profitability.
• R&D centers on stability, delivery ease, and new formulations, with regional markets in Asia-Pacific and Latin America expanding fastest.

FAQs

1. What factors primarily influence the growth of electrolyte solutions?
Healthcare infrastructure expansion, aging populations, and increasing chronic conditions driving electrolyte imbalance treatments.

2. How does patent expirations impact the market?
Patent expirations lead to increased generic competition, reducing prices and profit margins.

3. Which electrolyte component shows the highest adoption growth?
Sodium chloride remains the most widely used; however, phosphate and amino acid solutions are gaining traction in specialized care.

4. What regulatory challenges exist for new products?
FDA and EMA approval processes require extensive safety and efficacy data, impacting time-to-market and development costs.

5. Which regional markets show the highest growth potential?
Asia-Pacific and Latin America due to expanding healthcare infrastructure and rising demand for infusion therapies.

---

Sources

[1] Grand View Research, "Intravenous Solutions Market Size, Share & Trends Analysis Report," 2022.